Drug Profile
Research programme: ENT-1 inhibitors - Johnson and Johnson
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Johnson & Johnson Pharmaceutical Research & Development
- Developer Janssen Research & Development
- Class Benzamides; Spiro compounds
- Mechanism of Action Equilibrative nucleoside transporter 1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Inflammation; Pain
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Inflammation in Belgium
- 16 Jul 2016 No recent reports of development identified for preclinical development in Pain in Belgium
- 26 Aug 2010 Preclinical trials in Inflammation in Belgium (unspecified route)